Literature DB >> 21181270

Inter-ethnic variability of three functional polymorphisms affecting the IMPDH2 gene.

Anne Garat1, Christian Lacks Lino Cardenas, Arnaud Lionet, Aurore Devos, François Glowacki, Abderraouf Kenani, Florence Migot-Nabias, Delphine Allorge, Jean-Marc Lo-Guidice, Franck Broly, Christelle Cauffiez.   

Abstract

Human type II inosine monophosphate dehydrogenase (IMPDH2) is a key enzyme in the purine nucleotide biosynthetic pathway and constitutes a pivotal biological target for immunosuppressant and antiviral drugs. Several Single Nucleotide Polymorphisms (SNP) affecting the IMPDH2 gene sequence have been reported with potential functional relevance and could impact drugs response. We aimed to determine the frequency of three of these polymorphisms, namely g.3375C>T (Leu(263)Phe), c.-95T>G and IVS7+10T>C, in Caucasians, Tunisians, Peruvians and Black Africans (Gabonese and Senegalese). The g.3375C>T and c.-95T>G polymorphisms are rare with a Minor Allele Frequency ≤1.0% in our populations, whereas the third variant, IVS7+10T>C, is more frequent and displays large interethnic variations, with an allelic frequency ranging from 14.6% in the French Caucasian population studied to less than 2% in Black African and Peruvian populations. This ethnic-related data might contribute to a better understanding of the variability in clinical outcome and/or dose adjustments of drugs that are IMPDH inhibitors such as mycophenolic acid.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181270     DOI: 10.1007/s11033-010-0668-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  17 in total

1.  A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity.

Authors:  Jian Wang; Adriana Zeevi; Steve Webber; Diana M Girnita; Linda Addonizio; Rick Selby; Ian V Hutchinson; Gilbert J Burckart
Journal:  Pharmacogenet Genomics       Date:  2007-04       Impact factor: 2.089

Review 2.  Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics.

Authors:  Sonja B Braun-Sand; Matthew Peetz
Journal:  Future Med Chem       Date:  2010-01       Impact factor: 3.808

3.  Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.

Authors:  Olivier Gensburger; Ron H N Van Schaik; Nicolas Picard; Yannick Le Meur; Annick Rousseau; Jean-Baptiste Woillard; Teun Van Gelder; Pierre Marquet
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

4.  Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.

Authors:  T-Y Wu; Y Peng; L L Pelleymounter; I Moon; B W Eckloff; E D Wieben; V C Yee; R M Weinshilboum
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 5.  Mycophenolate mofetil: An update.

Authors:  Maria Cristina Villarroel; Manuel Hidalgo; Antonio Jimeno
Journal:  Drugs Today (Barc)       Date:  2009-07       Impact factor: 2.245

6.  Racial disparities in renal allograft survival: a public health issue?

Authors:  Devin E Eckhoff; Carlton J Young; Robert S Gaston; Steven W Fineman; Mark H Deierhoi; Margaret T Foushee; Robert N Brown; Arnold G Diethelm
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

7.  Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism.

Authors:  Ferdi Sombogaard; Ron H N van Schaik; Ron A Mathot; Klemens Budde; Marloes van der Werf; Arnold G Vulto; Willem Weimar; Petra Glander; Laurent Essioux; Teun van Gelder
Journal:  Pharmacogenet Genomics       Date:  2009-08       Impact factor: 2.089

8.  Cloning and sequence of the human type II IMP dehydrogenase gene.

Authors:  D A Glesne; E Huberman
Journal:  Biochem Biophys Res Commun       Date:  1994-11-30       Impact factor: 3.575

9.  Association of four DNA polymorphisms with acute rejection after kidney transplantation.

Authors:  Josep Grinyó; Yves Vanrenterghem; Björn Nashan; Flavio Vincenti; Henrik Ekberg; Klaus Lindpaintner; Michelle Rashford; Clare Nasmyth-Miller; Athina Voulgari; Olivia Spleiss; Matthew Truman; Laurent Essioux
Journal:  Transpl Int       Date:  2008-04-25       Impact factor: 3.782

Review 10.  Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression?

Authors:  G N Betonico; M Abudd-Filho; E M Goloni-Bertollo; E Pavarino-Bertelli
Journal:  J Nephrol       Date:  2008 Jul-Aug       Impact factor: 3.902

View more
  2 in total

1.  Arachidonic acid ω-hydroxylase CYP4A11: inter-ethnic variations in the 8590T>C loss-of-function variant.

Authors:  Christian Lacks Lino Cardenas; Aurore Devos; Aminata Toure; Jaime Cardenas Garcia; Abderraouf Kenani; Florence Migot-Nabias; Franck Broly; Dany Chevalier
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

2.  Expression of IMPDH mRNA after mycophenolate administration in male volunteers.

Authors:  Sollip Kim; Woochang Lee; Sail Chun; Tae Hyun Um; Won-Ki Min
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.